UNSPSC 51124203: Pyrinoline

This classification denotes an antiarrhythmic agent with the molecular formula C27H20N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 14PEC3LEVH, chemically known as 2-pyridinemethanol, alpha-(3-(di-2-pyridinylmethylene)-1,4-cyclopentadien-1-yl)-alpha-2-pyridinyl but more generally known as pyrinoline, which bears US NIH Compound Identifier 3052765. European Medicines Agency schedules Pyrinoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10171MIG.

UNSPSC 51124203 Pyrinoline is a Commodity code encompassing emergency pharmaceuticals and life-support medications procured by state and local public health agencies and municipal fire departments. State and local governments buy specific injectable medications—epinephrine, adenosine, labetalol, diltiazem, and related advanced life support drugs—for deployment by paramedics and rescue personnel. The issuing bodies soliciting under this code span city purchasing departments (municipal fire rescue services), state health and human services commissions, and multistate cooperative purchasing alliances. City of Tampa Fire Rescue, Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP, administered by the Minnesota Department of Administration) are recent buyers or market-intelligence gatherers in this space.

Activity is concentrated in Florida, Texas, and Minnesota based on recent postings. The City of Tampa issued an Invitation for Bid (26P00188) posted April 24, 2026, with a response deadline of April 8, 2026, seeking 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000.00 and SLBE sheltered-market designation offering a 5 percent bid discount not to exceed $10,000. Texas HHS issued a Request for Information (RFI HHS0017013) in March 2026 to explore direct-to-manufacturer pharmacy programs, signaling future formal procurement for pharmacy benefit management. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, requiring products available by May 15, 2026 for July 1, 2026 effective date, with pricing weighted at 75 percent of the evaluation and mandatory compliance with cGMP and Drug Supply Chain Security Act standards.